Page last updated: 2024-08-16

thalidomide and arq 197

thalidomide has been researched along with arq 197 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gandhi, V; He, J; Orlowski, RZ; Shentu, S; Stellrecht, CM; Yang, J; Zaman, S	1

Other Studies

1 other study(ies) available for thalidomide and arq 197

Article	Year
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:3 Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays	2015

Article

Year

Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.

Neoplasia (New York, N.Y.), 2015, Volume: 17, Issue:3

Topics: Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Lenalidomide; Melphalan; Mice; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Thalidomide; Tumor Microenvironment; Xenograft Model Antitumor Assays

2015